InMed Pharmaceuticals Inc. (INM)
NASDAQ · Healthcare
InMed Pharmaceuticals Inc. EBITDA 2021–2025
InMed Pharmaceuticals Inc. annual/quarterly ebitda history and growth rate from 2021 to 2023. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- InMed Pharmaceuticals Inc. ebitda for the quarter ending September 30, 2023 was -2.5 M, a 28.29% decrease year-over-year.
- InMed Pharmaceuticals Inc. ebitda for the twelve months ending September 30, 2023 was -9.9 M, a 23.14% decrease year-over-year.
- InMed Pharmaceuticals Inc. annual ebitda for 2023 was -7.7 M, a 57.94% decrease from 2022.
- InMed Pharmaceuticals Inc. annual ebitda for 2022 was -18.4 M, a 82.64% increase from 2021.
- InMed Pharmaceuticals Inc. annual ebitda for 2021 was -10.1 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
InMed Pharmaceuticals Inc. EBITDA — FAQ
InMed Pharmaceuticals Inc. (INM) ebitda over the last 5 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see INM's ebitda history?
The chart and table above show InMed Pharmaceuticals Inc.'s ebitda by year and by quarter, including the growth rate.